Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1374-1381

  Alan Anthoney, D ^a   McIlwrath, Amanda J ^a   Gallagher, William M ^a   Edlin, Angela R M ^a,b   Brown, Robert ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MICROSATELLITE DNA; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL LOSS; CROSS RESISTANCE; DNA DAMAGE; GENE INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STABILITY; TRANSCRIPTION REGULATION; TUMOR CELL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; DNA, SATELLITE; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; HUMANS; INTERPHASE; MICROSATELLITE REPEATS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PHENOTYPE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029985445     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Hamaguchi, K , Godwin, A. K., Yakushiji, M., O'Dwyer, P. J., Ozols, R. F., and Hamilton, T. C. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res., 53: 5225-5232, 1993.
2. Kaye, S. B The multidrug resistance phenotype. Br. J Cancer, 58: 691-694, 1988
3. Epstein, R. J. Drug-induced DNA damage and tumour chemosensitivity. J. Clin. Oncol., 8: 2062-2084, 1990.
4. Andrews, P. A , and Howell, S. B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells, 2: 35-43, 1990
5. Gottesman, M M How cancer cells evade chemotherapy. Cancer Res., 53: 747-754, 1993.
6. Hickman, J. A. Apoptosis induced by anticancer agents Cancer Metastasis Rev , 11 121-139, 1992
7. Clarke, A. R., Purdie, C. A , Harrison, D. J., Morris, R G., Bird, C. C , Hooper, M. L , and Wylhe, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
8. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
9. Oltvai, Z N , Milliman, C. L., and Korsmeyer, S. J BCL-2 heterodimerizes in vivo with a conserved homolog, BAX, that accelerates programed cell death. Cell, 74: 609-619, 1993.
10. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
11. McIllwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R Cell cycle arrests and radiosensitivity of human tumour cell lines: dependence on wild-type p53 for radiosensitivity Cancer Res., 54 3718-3722, 1994.
12. 1 arrest and apoptosis Cancer Res , 54: 1169-1174, 1994.
13. Sherman, S E , and Lippard, S J Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev., 87: 1153-1181, 1987.
14. Hesger-Bernays, W. J., Essigmann, J. M., and Lippard, S. J Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry, 29: 8461-8466, 1990
15. Evans, D. L , Tilby, M., and Dive, C Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the level of drug accumulation and DNA adduct formation. Cancer Res., 54: 1596-1603, 1994.
16. Blum, R H., and Carter, S. K Adriamycin. a new anticancer drug with significant clinical activity Ann. Intern. Med., 80: 249-267, 1974
17. Skladanowski, A., and Konopa, J. Relevance of interstrand DNA crosslinking induced by anthracyclines for their biological activity. Biochem. Pharmacol., 47 2279-2287, 1994
18. Mamenta, E. L., Poma, E. E., Kaufmann, W. K , Delmastro, D. A., Grady, H. L., and Chaney, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
19. Kat, A., Thilly, W. G., Fang, W. Longley, M J , Li, G , and Modrich, P An alkylating-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl Acad Sci. USA, 90 6424-6428, 1993.
20. Aquilina, G., Hess, P , Branch, P , MacGeoch, C., Casciano, I., Karran, P., and Bignami, M A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. Proc. Natl. Acad. Sci. USA, 91 8905-8909, 1994.
21. + tumor cells. Cell, 75: 1227-1236, 1993.
22. Horii, A., Han, H J , Shimada, M., Yanagisawa, A., Kato, Y., Ohta, H., Yasui, W., Tahara, E , and Nakamura, Y. Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. Cancer Res., 54: 3373-3375, 1994.
23. Loeb, L. A. Microsatellite instability: marker of a mutator phenotype in cancer Cancer Res , 54: 5059-5063, 1994.
24. Leach, F. S., Nicolaides, N. C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R , Peltomaki, P., Sistonen, P., Aaltonen, L A., and Nystrom-Lahti, M Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell, 75: 1215-1225, 1993
25. Bronner, C. E., Baker, S. M., Morrison, P. T., Warren, G., Smith, L. G., Lescoe, M. K., Kane, M , Earabino, C., Lipford, J., and Lindblom, A. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer Nature (Lond.), 368. 258-261, 1994.
26. Papadopoulos, N., Nicolaides, N. C., Wei, Y., Ruben, S M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C M., Adams, M. D., Venter, J. C., Hamilton, S. R., Petersen, G. M , Watson, P., Lynch, H T., Peltomaki, P., Mecklin, J., de la Chapelle, A , Kinzler, K. W., and Vogelstein, B Mutation of a mutL homolog in hereditary colon cancer. Science (Washington DC), 263: 1625-1628, 1994.
27. Feng, W. Y., Lee, E. H., and Hays, J. B. Recombinagenic processing of UV-light photoproducts in nonreplicating phage DNA by the Escherichia coli methyl-directed mismatch repair system. Genetics, 129: 1007-1020, 1991.
28. Fram, R, J., Cusick, P. S., Wilson, J. M., and Mannas, J M. Mismatch repair of cis-diamminedichloroplatinum II-induced DNA damage Mol. Pharmacol., 28: 51-55, 1985.
29. Behrens, B. C., Hamilton, T. C , Masuda, H., Grotzinger, K. R., Whang-Peng, J , Lome, K. G., Knutsen, T., McKoy, W M., Young, R. C , and Ozols, R. F. Characterisation of a cis-diamminedichloroplatinum II resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47. 414-418, 1987.
30. Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, R W., and Ozols, R. F. Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science (Washington DC), 224: 994-996, 1984.
31. Cowan, K. H., Bastist, G., Tulpule, A., Sinha, B. K., and Myers, C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats Proc. Natl. Acad Sci USA, 83: 9328-9332, 1986.
32. McLaughlin, K., Stephens, I., McMahon, N , and Brown, R. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line Cancer Res., 51. 2242-2245, 1991
33. Anderson, L. A., Friedman, L., Osborne-Lawrence, S., Lynch, E., Weissenbach, J., Bowcock, A., and King, M. High density genetic map of the BRCA-I region of chromosome 17q12-21. Genomics, 17: 618-623, 1993.
34. Don, R. H., Cox, P T , Wainwright, B. J., Baker, K., and Mattick, J. S. "Touchdown" PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res., 19 4008-4009, 1991.
35. Jiricny, J , Hughes, M., Corman, N., and Rudkin, B B. A human 200-kDa protein binds selectively to DNA fragments containing G-T mismatches. Proc. Natl Acad. Sci. USA, 85: 8860-8864, 1988.
36. Griffin, S., and Karran, P. Incision at DNA G.T mispairs by extracts of mammalian cells occurs preferentially at cytosine methylation sites and is not targeted by a separate G.T binding reaction. Biochemistry, 32: 13032-13039, 1993.
37. Vojtesek, B , Bartek, J., Midgley, C. A., and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. new monoclonal antibodies and epitope mapping using recombinant p53 J. Immunol Methods, 151: 237-244, 1992.
38. Kokileva, L. Endogenous degradation of rat liver chromatin studied by agar gel electrophoresis of nuclei. Mol. Biol. Reports, 13: 139-143, 1989.
39. Filipski, J., Leblanc, J., Youdale, T., Sikorska, M., and Walker, P R. Periodicity of DNA folding in higher order chromatin structures. EMBO J., 9: 1319-1327, 1990.
40. Gorczyca, W , Gong, J., Ardelt, B., Traganos, F , and Darzynkiewicz, Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumour agents Cancer Res , 53. 3186-3192, 1993.
41. El-Deiry, W. S., Tokino, T., Velculescu, V. E , Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF-1, a potential mediator of p53 tumour suppression. Cell, 75: 817-825, 1993
42. Tso, J. Y., Sun, X., Kao, T., Reece, K. S., and Wu, R. Isolation and characterisation of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evolution of the gene. Nucleic Acids Res., 13: 2485-2488, 1985.
43. Orth, K., Hung, J., Gazdar, A., Bowcock, A., Mathis, J M., and Sambrook, J. Genetic instability in human ovarian cancer cell lines. Proc. Natl Acad. Sci USA, 91. 9495-9499, 1994
44. + tumour cells. Cell, 75. 1227-1236, 1993.
45. Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E , Walker, P. R., and Sikorska, M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J., 12: 3679-3684, 1993.
46. Parker, R J , Eastman, A , Bostick-Bruton, F., and Reed, E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin. Invest., 87: 772-777, 1991.
47. Eliopoulos, A. G , Kerr, D J , Herod, J., Hodgkins, L., Krajewski, S , Reed, J. C , and Young, L. S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene, 11: 1217-1228, 1995
48. Vasey, P. A., Jenkins, S., Bissett, D., and Brown, R p53-mediated multi-agent resistance and approaches to circumvention in a human ovarian cell line Br J Cancer, 71: 7, 1995.
49. Brown, R., Clugston, C., Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. B. Increased accumulation of p53 in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678-684, 1993.
50. Miyashita, T., Harigai, M., Kanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994.
51. Livingstone, W. R., White, A., Sprouse, J., Livanose, E , Jacks, T., and Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992
52. Parsons, R., Li, G., Longley, M., Modrich, P., Liu, B., Berk, T., Hamilton, S. R , Kinzler, K. W., and Vogelstein, B. Mismatch repair deficiency in phenotypically normal human cells Science (Washington DC), 268: 738-740, 1995.
53. Branch, P , Aquilina, G., Bignami, M , and Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (Lond.), 362: 652-654, 1993.
54. Peng, H., Hogg, D., Malkin, D., Bailey, D., Gallie, B. L , Bulbul, M., Jewett, M , Buchanan, J., and Goss, P E. Mutations of the p53 gene do not occur in testis cancer. Cancer Res., 53: 3574-3578, 1993.
55. Al-Azraqi, A., Chapman, C., Challen, C., Sigalas, J., Aswaad, S., Sinha, D., Calvert, A. H., and Lunec, J. p53 alterations in ovarian cancer as a determinant of response to carboplatin. Br. J. Cancer, 69: 7, 1994.